Navigation Links
For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019
Date:12/16/2010

BURLINGTON, Mass., Dec. 16, 2010 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to its superb efficacy, acceptable safety profile and anticipated launch in all major markets, Ironwood/Forest/Almirall/Astellas's linaclotide will emerge as the market leader for the treatment of irritable bowel syndrome (IBS). In 2019, linaclotide will garner blockbuster sales of $1.1 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

Although Sucampo/Takeda/Abbott's Amitiza was the IBS drug market leader in 2009, the drug's limited efficacy, loss of patent protection and competition from linaclotide will cause Amitiza's sales to drop sharply through 2019.

The findings from the Pharmacor topic entitled Irritable Bowel Syndrome, which will publish later this month, reveal that the overall IBS drug market will expand at a 14 percent annual rate from 2009 to 2019, owing to the market entry of much-needed first-in-class therapies.

The findings also reveal that, because of the heterogeneity of IBS and the high rate of generic penetration, the IBS therapy market is highly fragmented and underserved. The lack of prescription therapies that can address more than one symptom of the disease means that physicians and patients resort to using multiple drugs, many of which are inadequate at controlling motility or pain symptoms associated with IBS. Additionally, owing to the combination of high prevalence and low diagnosis rates, substantial commercial potential exists for the development of drugs that target this indication.  

"IBS is a highly prevalent chronic condition in the world's major pharmaceutical markets, but the lack of a biochemical or histological marker for positive diagnosis and incomplete understanding of the disease's pathophysiology and etiology have resulted in low diagnosis and treatment rate
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Accuray Receives FDA Clearance for the CyberKnife® Systems Lung Optimized Treatment
2. Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies
3. MHRA Issues Notice of Acceptance for Phase 3 Trial of GALNS for the Treatment of MPS IVA
4. ISTA Pharmaceuticals Initiates Phase 2 Clinical Study of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
5. FDA Approves PREZISTA®/ritonavir Once-Daily Dosing for HIV-1 Treatment-Experienced Adults With No Darunavir Resistance-Associated Mutations
6. NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
7. Physiotherapy Associates Announces New Multiple Sclerosis Specialty Treatment Program
8. Reportlinker Adds Prostate Cancer - Italy Drug Forecasts and Treatment Analysis to 2020
9. Cancer Treatment Centers Oncology Information System Options Expand with New MOSAIQ Connectivity
10. Reportlinker Adds Prostate Cancer - Spain Drug Forecasts and Treatment Analysis to 2020
11. Reportlinker Adds Prostate Cancer - Japan Drug Forecasts and Treatment Analysis to 2020
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Aug. 22, 2014 MC Medical, a subsidiary of ... Columbus, OH medical device company, have ... laparoscopic and robotic visualization system in Japan ... sale in Japan in the latter ... and an extensive product portfolio in endoscopic surgery market in ...
(Date:8/22/2014)... 22, 2014 Research and Markets ... Chinese Particulate Respirators Industry Report 2014" report to ... Particulate Respirators Industry Report 2014 is a professional and ... particulate respirators industry with a focus on the Chinese ... the industry including definitions, classifications, applications and industry chain ...
(Date:8/22/2014)... August 22, 2014 ... Today Lincor announced general availability of ... that delivers a range of education, entertainment and clinical ...      (Logo: http://photos.prnewswire.com/prnh/20140822/702945) , " ... of care patient engagement to bedside smart devices, " ...
Breaking Medicine Technology:MC Medical agrees to be the exclusive distributor of FloShield products in Japan 2Global and Chinese Particulate Respirators Industry Report 2014 2Lincor Unveils Next Generation TV-based Patient Engagement Solution 2
... April 10, 2012 /PRNewswire-Asia/ -- China Botanic Pharmaceutical ... Botanic" or the "Company"), a developer, manufacturer and ... medicines ("TCM") in China, today announced the results ... Meeting") held on Tuesday, April 10, 2012 (Beijing ...
... Mylan Inc. (Nasdaq: MYL ) announced today that ... Thursday, April 26, 2012, at 10:00 a.m. ET, to review ... ended March 31, 2012. Mylan will release its financial results ... dial-in number to access the call is 877.402.3913 or 817.382.5964 ...
Cached Medicine Technology:China Botanic Announces Results of Annual General Meeting 2
(Date:8/22/2014)... Beat Eczema , Susan Clark’s ... natural methods to completely cure the eczema symptoms they ... Shane Michaels, prompting an investigative review. , “Although ... it can still be extremely debilitating and life-altering for ... itching and pain that it causes on the skin ...
(Date:8/22/2014)... the first time an oncogenic somatic mutation at amino ... has been identified in small cell lung cancer (SCLC) ... cell lines produced increased intracellular signaling and cell growth. ... cancer representing 15% of all lung cancers and is ... lung cancer, has been extensively examined for genomic alterations ...
(Date:8/22/2014)... August 22, 2014 Paying tuition and ... in the coming year for four nurse educators pursuing ... National League for Nursing Foundation for Nursing Education . ... share $28,000, $10,000 more than in 2013, thanks to ... Endowment and Elizabeth Isaac Marcil Endowment Funds, both donated ...
(Date:8/22/2014)... New York, New York (PRWEB) August 22, 2014 ... ) continue to be filed in U.S. courts ... cardiovascular events due to their use of prescription ... to court documents, a new claim was filed ... California man who allegedly suffered life-threatening heart issues ...
(Date:8/22/2014)... 2014 CarePoint Health is proud ... Medicine, Geriatrics, Hospice and Palliative Care, Dr. Michelle ... Group. Their system welcomes Dr. Reisner to the ... comprise CarePoint Health Medical Group, a comprehensive network ... representing a wide range of specialties. This latest ...
Breaking Medicine News(10 mins):Health News:Beat Eczema: Review Exposes Susan Clark’s Guide to Curing Eczema Naturally 2Health News:Novel oncogenic RET mutation found in small cell lung cancer 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 2Health News:NLN Foundation for Nursing Education Announces 2014 Faculty Scholarship Awards 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4Health News:Dr. Reisner Joins CarePoint Health Medical Group 2
... HARRISBURG, Pa. , Jan. 18 Be active to ... Department of Health are conveying to middle school-aged children throughout the ... statewide program kicks off locally at 1:30 p.m. Wednesday, Jan. ... Steelton-Highspire Middle School is an Active Schools grant recipient. ...
... with affect your behavior, for good or bad, research ... you spend time with people who exhibit self-control -- ... instance -- you can expect your own self-control to ... But the opposite seems true, too: Spending time with ...
... KNOXVILLE, Tenn. , Jan. 18 Remote Area Medical®, ... countries and in the U.S., announced today that it will be ... earthquake relief efforts at the Jimani Project facility in Jimani, ... Brock and RAM volunteers loaded more than a ton of ...
... during female ovulation, study finds , MONDAY, Jan. ... a man,s attention shouldn,t wear perfume, new research suggests. ... and Jon K. Maner found that male testosterone levels ... during ovulation, which is when women are most fertile. ...
... Renée ... Health. , ... Heights, N.J. (Vocus) January 18, 2010 -- Renée Schreiber Chervenak, M.D., has recently joined ... Chervenak earned her B.A. summa cum laude at Boston University College of Engineering and ...
... ... osteoporosis everyday because of common misconceptions about the disease. Dr. Karl R.O.S. Johnson, D.C. describes ... osteoporosis - without dangerous medications. , ... (PRWEB) January 18, 2010 -- The National Osteoporosis Foundation in the United States has ...
Cached Medicine News:Health News:Capital BlueCross Partners with Department of Health, Area Schools to Encourage Students to Lead Active, Healthy Lifestyles 2Health News:Capital BlueCross Partners with Department of Health, Area Schools to Encourage Students to Lead Active, Healthy Lifestyles 3Health News:Self-Control Just Might Be Contagious 2Health News:Self-Control Just Might Be Contagious 3Health News:Remote Area Medical Travels to Haiti to Assist in Earthquake Relief Efforts 2Health News:Remote Area Medical Travels to Haiti to Assist in Earthquake Relief Efforts 3Health News:Summit Medical Group Welcomes Rene Schreiber Chervenak, M.D. 2Health News:Medical Breakthrough: Drug Free Strategy Shows Promise for Reversing or Halting Osteoporosis for Michigan Men and Women 2